¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Blood Group Antigens"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • blood count
    Ç÷±¸°è»ê
  • blood crust
    ÇǵüÁö
  • blood depot reservoir
    Ç÷¾×ÀúÀå¼Ò
  • blood derivative
    Ç÷¾×À¯µµÃ¼
  • blood disk
    Ç÷¼ÒÆÇ
  • blood donation
    ÇåÇ÷
  • blood donor
    ÇåÇ÷ÀÚ, °øÇ÷ÀÚ
  • blood dust
    ÇǸÕÁö, Ç÷Áø
  • blood dyscrasia
    Ç÷¾×º´
  • blood enzyme level
    Ç÷ÁßÈ¿¼Ò³óµµ
  • blood film
    Ç÷¾×Æì¹Ù¸¥Ç¥º», Ç÷¾×µµ¸»
  • blood flow
    1. Ç÷·ù 2. Ç÷·ù·®
  • blood flow meter
    Ç÷·ù°è
  • blood flow rate
    1. Ç÷·ù·® 2. Ç÷·ù¼Óµµ
  • blood fluke
    ÁÖÇ÷ÈíÃæ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • artificial blood
    ÀΰøÇ÷¾×
  • autologous blood
    ÀÚ°¡Ç÷¾×
  • automated noninvasive blood pressure device
    ºñħ½ÀÀÚµ¿Ç÷¾Ð±â
  • blood gas apparatus
    Ç÷¾×°¡½ººÐ¼®ÀåÄ¡
  • soybean-casein digest blood agar
    ¼ÒÀ̺óÄ«Á¦ÀμÒÈ­Ç÷¾×¿ì¹«
  • blood
    Ç÷¾×, ÇÇ
  • bank blood
    ÀúÀåÇ÷¾×
  • basal blood pressure
    ±âÀúÇ÷¾Ð
  • blood bank
    Ç÷¾×ÀºÇà
  • blood bicarbonate
    Ç÷¾×Áßź»ê¿°
  • blood cell
    Ç÷¾×¼¼Æ÷, Ç÷±¸
  • blood clot
    Çǵ¢ÀÌ, ÇǶ±
  • blood coagulation
    Ç÷¾×ÀÀ°í
  • blood collection
    äÇ÷
  • blood concentration
    Ç÷Áß³óµµ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • placental blood
    ŹÝÇ÷(÷ÃÚïúì)
  • placental blood space
    ŹÝÇ÷¾×°­ (¡­úìäûË·).
  • pooled blood plasma
    È¥ÁÖÇ÷Àå(ûèñ¬úìíì).
  • pooled blood plasma
    È¥ÁÖÇ÷Àå(ûèñ¬úìíì)
  • portal blood pressure
    ¹®¸Æ¾Ð(Ú¦Øæäâ).
  • preserved blood =conserved b.
    º¸Á¸Ç÷(¾×)(ÜÁðíúì(äû))
  • pulmonary blood flow
    ÆóÇ÷·ù·®(øËúìêüåÖ).
  • rabbit blood agar
    Åä³¢Ç÷(¾×)ÇÑõ
  • red blood cell
    ÀûÇ÷±¸
  • red blood cell cast
    ÀûÇ÷±¸¿øÁÖ
  • red blood cell destruction
    ÀûÇ÷±¸ºØ±«(îåúìϹÝÚÎÕ)
  • red blood cell pasta
    ÀûÇ÷±¸È£Á¦(¡­ûÕð¥).
  • red blood cell survival test
    ÀûÇ÷±¸¼ö¸í½ÃÇè(îåúìϹáøÙ¤ãËúÐ).
  • red blood cell=RBC
    ÀûÇ÷±¸
  • red blood corpuscle
    ÀûÇ÷±¸.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • group IV fiber
    Á¦¥³¤Çí·A.
  • group Ia inhibition
    ¥°a±º¾ïÁ¦(ÏØàéë«).
  • group Ia inhibition
    ¥°a¤ÇϹA.
  • group antigen
    ±ºÇ׿ø(ÏØù÷ê«).
  • group audiometry
    Áý´Üû·Â°Ë»ç(¹ý)
  • group conformity rating =GCR
    Áý´ÜÇÕÄ¡ µî±ÞºÐ·ù(ÊṴ̬̀ËÄË»ËÓËÈ).
  • group discussion
    Áý´ÜÅäÀÇ(̤ËÀ̬Ëö).
  • group displacement law
    Áý´Üº¯À§¹ýÄ¢(ÊÙËÒ ËôËÑ̬).
  • group dynamics
    Áý´Ü¿ªÇÐ(ÊÙËç ).
  • group file
    ±×·ì È­ÀÏ
  • group hearing aid
    Áý´Üº¸Ã»±â
  • group hospital
    º´¿øÁ¶ÇÕ(ËÓËô̡̰).
  • group incompatibility
    Ç÷¾×±ººÎÀûÇÕ(úìäûÏØ ÝÕîêùê).
  • group medicine
    Áý´Ü<Çùµ¿>Áø·á.
  • group of isogenous chondrocyte
    ¿¬°ñ¼¼Æ÷¹«¸®
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • haptenic group
    ÇÕÅÙ±â(Ðñ)
  • high-mobility group
    °íÀ̵¿µµ ±º(ÍÔì¹ÔÑÓøÏØ)
  • hydroxyl group
    ÇÏÀ̵å·Ï½Ç±â(Ðñ)
  • hydroxymethyl group
    ÇÏÀ̵å·Ï½Ã¸ÞÆ¿±â(Ðñ)
  • hypsochromic group
    û»öÀ̵¿±â(ôìßäì¹ÔÑÐñ)
  • imidazole group
    À̴̹ÙÁ¹±â(Ðñ)
  • imino group
    À̹̳ë±â(Ðñ)
  • Inv group
    Inv ±º(ÏØ)
  • ketone group
    ÄÉÅæ±â(Ðñ)
  • labile methyl group
    ºÒ¾ÈÁ¤(ÝÕäÌïÒ)¸ÞÆ¿±â(Ðñ)
  • labile phosphate group
    ºÒ¾ÈÁ¤Àλê±â(ÝÕäÌïÒ×ò߫Ѩ)
  • leaving group
    ÀÌÅ»±â(×î÷­Ðñ)
  • linkage group
    ¿¬°ü±º(Ö¤Î¼ÏØ)
  • mercapto group
    ¸Ó°©Åä±â(Ðñ)
  • methenyl group
    ¸ÞÅ×´Ò±â(Ðñ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
MBF medullary blood flow; muscle blood flow; myocardial blood flow
NRBC National Rare Blood Club; normal red blood cell; nucleated red blood cell
RBC red blood cell; red blood corpuscle; red blood count
WBC well baby care/clinic; white blood cell; white blood cell count; whole blood cell count
AB abdominal; abnormal; abortion; Ace bandage; active bilaterally; aid to the blind; alcian blue; alert...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
EBMT European Group for Blood and Marrow Transplantation
ACTG AIDS Clinical Trials Group
ACG Ambulatory Care Group
AN-DRG Australian National Diagnosis Related Group
BILAG British Isles Lupus Assessment Group
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • blood line
    Ç÷Á·, Ç÷Á·°è
  • blood loss
    ½ÇÇ÷
  • blood oxygenation level dependant
    Ç÷Áß »ê¼ÒÄ¡ ÀÇÁ¸
  • blood perfusion
    Ç÷¾× °ü·ù
  • blood pigment
    Ç÷»ö¼Ò
    µ¿ÀǾî=hemoglobin.
  • blood plasma substitute
    ´ë¿ë Ç÷Àå
  • blood poison
    Ç÷¾× µ¶
    ¿©·¯ °¡Áö ÀǾàǰÀ̳ª È­Çоàǰ ¶Ç´Â ¾î¶² Á¾ÀÇ µ¿½Ä¹°ÀÇ ¿¢½º
  • blood pool scan
    Ç÷¾× Àú·ù ÁÖ»ç
  • blood preservation
    Ç÷¾× º¸Á¸
  • blood pressure cuff
    Ç÷¾Ð°è³¶´ë
  • blood pressure manometer
    Ç÷¾Ð°è
    ÀÎüÀÇ Ç÷¾ÐÀ» ÃøÁ¤ÇÏ´Â ±â±¸. ¸Æ¾Ð°è¶ó°íµµ ÇÑ´Ù. Á÷Á¢¹ý°ú °£Á¢¹ý
  • blood product
    Ç÷¾× Á¦Á¦
  • blood recipient
    ¼öÇ÷ÀÚ
  • blood sample
    Ç÷¾× Ç¥º», Ç÷¾× »ùÇÃ
  • blood serum
    Ç÷û
    1. Ç÷¾×ÀÌ ¿ÏÀüÈ÷ ÀÀ°íµÈ ´ÙÀ½ Ç÷¾×¿¡¼­ À¯¸®µÈ Åõ¸íÇÑ ¾×ü·Î, ÀÀ°í °úÁ¤¿¡ À־ Ç÷ÀåÀ¸·ÎºÎÅÍ ¼¶À¯¼Ò¿øÀÌ Á¦°ÅµÈ °Í. 2. Ç÷Àå¿¡¼­ ¼¶À¯¼Ò¿øÀ» Á¦°ÅÇÑ ³ª¸ÓÁö. »ýü¿¡¼­ äÃëÇÑ Ç÷¾×À» ½ÃÇè°ü¿¡ ³Ö¾î Á¶¿ëÈ÷ ¼¼¿öµÎ¸é ¸ÕÀú ÀÀ°íÇÏ¿© ÀÀÇ÷ÀÌ µÇ°í, À̰ÍÀÌ ¼öÃàÇÏ¿© ¾ÏÀû»öÀÇ µ¢¾î¸®ÀÎ Ç÷º´°ú ´ãȲ»öÀÇ Åõ¸íÇÑ ¾×üÀÎ Ç÷ûÀ¸·Î ³ª´©¾îÁø´Ù. Áï, Ç÷¾×¿¡¼­ À¯Çü ¼ººÐ ÀÌ¿ÜÀÇ ºÎºÐÀº Ç÷ÀåÀε¥, ÀÌ Ç÷Àå¿¡¼­ ¼¶À¯¼Ò¿ø
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
antigens, CD8 <immunology> Differentiation antigens found on thymocytes and on cytotoxic and suppressor T-lymphocytes. Cd8 antigens are members of the immunoglobulin supergene family and are associative recognition elements in major histocompatibility complex class I-restricted interactions.
(12 Dec 1998)
antigens, CD80 <immunology> The natural ligand for the T-cell antigen CD28 (antigens, CD28) mediating t-cell and B-cell adhesion. Cd80 is expressed on activated B-cells and gamma-interferon-stimulated monocytes. The binding of CD80 to CD28 and ctla-4 provides a co-stimulatory signal to T-cells and leads to greatly upregulated lymphokine production.
(12 Dec 1998)
antigens, CD95 <immunology> Differentiation antigens expressed on a variety of cell lines including myeloid and lymphoblastoid cell lines. Their primary role is to regulate peripheral immune responses, which is achieved by triggering apoptosis.
(12 Dec 1998)
antigens, differentiation Antigens expressed primarily on the membranes of living cells during sequential stages of maturation and differentiation. As immunologic markers they have high organ and tissue specificity and are useful as probes in studies of normal cell development as well as neoplastic transformation.
(12 Dec 1998)
antigens, differentiation, b-lymphocyte Membrane antigens associated with maturation stages of B-lymphocytes, often expressed in tumours of B-cell origin.
(12 Dec 1998)
antigens, differentiation, myelomonocytic Surface antigens expressed on myeloid cells of the granulocyte-monocyte-histiocyte series during differentiation. Analysis of their reactivity in normal and malignant myelomonocytic cells is useful in identifying and classifying human leukaemias and lymphomas.
(12 Dec 1998)
antigens, differentiation, t-lymphocyte Antigens expressed on the cell membrane of T-lymphocytes during differentiation, activation, and normal and neoplastic transformation. Their phenotypic characterization is important in differential diagnosis and studies of thymic ontogeny and T-cell function.
(12 Dec 1998)
antigens, fungal Substances of fungal origin that have antigenic activity.
(12 Dec 1998)
antigens, helminth Any part or derivative of a helminth that elicits an immune reaction. The most commonly seen helminth antigens are those of the schistosomes.
(12 Dec 1998)
antigens, heterophile Antigens stimulating the formation of, or combining with heterophile antibodies. They are cross-reacting antigens found in phylogenetically unrelated species.
(12 Dec 1998)
antigens, human platelet Human alloantigens expressed only on platelets, specifically on platelet membrane glycoproteins. These platelet-specific antigens are immunogenic and can result in pathological reactions to transfusion therapy.
(12 Dec 1998)
antigens, ly A group of lymphocyte surface antigens differentially located on subpopulations of mouse lymphocytes. This localization has been useful in distinguishing different functional subpopulations of lymphocytes. For example, cytotoxic T-cells bear primarily lyt-23 on their surface and not lyt-1, whereas helper cells bear lyt-1 and not lyt-23.
(12 Dec 1998)
antigens, neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumour cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
(12 Dec 1998)
antigens, polyomavirus transforming Polyomavirus antigens which cause infection and cellular transformation. The large t antigen is necessary for the initiation of viral DNA synthesis, repression of transcription of the early region and is responsible in conjunction with the middle t antigen for the transformation of primary cells. Small t antigen is necessary for the completion of the productive infection cycle.
(12 Dec 1998)
antigens, protozoan Any part or derivative of any protozoan that elicits immunity; malaria (plasmodium) and trypanosome antigens are presently the most frequently encountered.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • group velocity
    (ÆÄµ¿ÀÇ)±º¼Óµµ
  • group work
    Áý´Ü(»çȸ)»ç¾÷
  • habitat group
    »ýÅ·ù(¼­½Ä ȯ°æÀ» °°ÀÌ ÇÏ´Â µ¿½Ä¹°);(¹Ú¹°°ü¿¡ Àü½ÃµÈ)»ý¹° ȯ°æ ¸ðÇü
  • income group
    »çȸ ¼ÒµæÃþ(µ¿ÀÏ ¼Òµæ¼¼¾×Áý´Ü)
  • informal group
    (»çȸ)ºñ°ø½ÄÀû Áý´Ü(°üû°øÀåµî¿¡¼­ÀÇ)
  • interested group
    (»çȸ)ÀÌÀͰøµ¿Ã¼;°øÅëÀÌÇØ´Üü(±¹°¡ Á¤´çŬ·´µî)
  • minority group
    ¼Ò¼ö¹ÎÁ·(Çѳª¶óÀÇ)
  • peer group
    µ¿·á Áý´Ü;µ¿¹è Áý´Ü
  • pressure group
    ¾Ð·Â ´Üü
  • primary group
    Á¦ ÀÏÂ÷ Áý´Ü(°¡Á¤,Ä£±¸ µî)
  • rape group
    ÅäÀÇ(Åä·Ð)±×·ì
  • reference group
    ÁذŠÁý´Ü(°³ÀÎÀÌ ÀÚ±â ŵµ.ÆÇ´ÜÀÇ ±âÁØÀ¸·Î ¿©±â´Â ƯÁ¤ Áý´Ü)
  • splinter group
    ºÐÆÄ;¼Ò¼öÆÄ
  • tail group
    TAIL UNIT
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á